MARKER THERAPEUTICS, INC. MRKR Cash Flow

Marker therapeutics, inc. (MRKR)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12
Cash Flows from Operating Activities:
Net loss
-6,485	-	-	-	-5,318	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-4,812	-3,196	-2,683	-3,985	-1,893	-2,419	-1,576	-2,102	5,974	-4,749	-1,652	28,503	-60,216	-700	-736	-1,192	753	-29,707	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-441	-2,053	-768	-2,752	-598
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization
35	34	31	29	10	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in fair value of warrant liabilities
-31	-98	64	7	9	-58	-40	139	-1	3	-4	-7	3	-14	-684	-8,237	2,996	-613	-30,266	59,079	-327	242	-228	-352	338	-	-	-	-	-	-	-	-
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Shares issued in debt settlement agreements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	104	96	0	-19	-85	0	0
Non-cash interest and financing charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-96	96
Stock-based compensation
1,344	1,283	1,184	1,363	1,525	14,402	851	960	136	405	1,685	271	376	249	764	330	214	1,443	13	244	3	125	466	109	690	10	10	27	83	9	141	2,125	163
Amortization on right-of-use assets
47	46	45	44	44	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on extinguishment of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46	94	-920	27,663	-	-	-	-	-	-	-	-
Non-cash interest and finance charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	483	-	-	-	-	-	-	-	-
Changes in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,097	-315	121	352	71
Loss on settlement of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	436	-	-	-	-
Loss (gain) on settlement of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	18	9
Gain on extinguishment of derivative liabilities- warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Loss on disposal of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Non-cash interest and finance charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Changes in operating assets and liabilities:
Prepaid expenses and deposits
189	-379	1,414	275	74	44	-11	-20	77	-45	-82	1	107	-41	90	-16	-31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest receivable
-31	-21	-20	-14	4	108	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Due from government agency
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-0	0	-0	0
Prepaid expenses and deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	103	0	-207	103	-7	-3	-15	-15
Deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	6	27	-10	4	8	-3	-3
Accounts payable and accrued expenses
1,197	-1,101	-87	252	-27	-839	-6	1,293	792	-248	195	111	224	-453	140	-108	678	-108	55	139	9	-436	-30	163	158	1,118	-347	433	630	1,075	350	565	24
Lease liability
-49	-48	-46	-45	-44	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability
-49	-48	-46	-45	-44	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,954	-829	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research agreement obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	48	27	50	44	17	43
Net cash used in operating activities
-4,099	-4,560	-5,663	-4,179	-3,880	-6,162	-3,571	-2,399	-2,346	-2,478	-2,025	-2,011	-1,923	-	-	-	-	-	-	-813	-1,014	-669	-906	-238	-372	59	-134	-165	-454	-492	-272	-491	-332
Cash Flows from Investing Activities:
Purchase of property and equipment
99	12	56	82	223	147	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Cash acquired on reverse acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Net cash used in investing activities
-99	-12	-56	-82	-223	-147	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Cash Flows from Financing Activities:
Proceeds from exercise of stock options
-	0	0	0	57	0	0	0	18	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
550	0	753	0	5	9	83	4,261	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Issuance of shares, net of finders' fee
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2,326	-	-	583	0	-231	-4	0	235	100	0	370	85
Repayment of promissory note
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-25	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32	0	0	0	-18	3	18	0
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-25	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible note issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	418	-196	698	236	0	396	206	0	0
Notes and loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Advances from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80	-	-	-	20
Repayment of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	179	-159	-108	108	-	-	-	-
Stock subscriptions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Net cash provided by financing activities
550	0	753	0	63	63,762	83	7,381	18	0	-329	6,047	0	-	-	-	-	-	-	2,465	2,326	197	1,499	165	418	-16	94	205	425	522	264	479	105
Net decrease in cash
-3,648	-4,573	-4,967	-4,261	-4,040	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash
-	-	-	-	-	-	-	-	-2,328	-2,478	-2,354	4,035	-1,923	-1,735	5,819	-1,954	-854	489	2,981	1,651	1,311	-471	592	-72	45	43	-40	40	-29	30	-8	-11	-226
Supplemental schedule of non-cash financing activities:
Issuance of common stock as commitment fee for future financing
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilsons compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	191	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of issuance of warrants in January and March 2015 financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	9,313	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable settled in common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,732	0	170	513	-	-	-	-	-	-	-	-
Fair value of issuance of warrants in January an March 2015 financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49	0	0	476	-	-	-	-	-	-	-	-
Convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	319	0	504	3,293	-	-	-	-	-	-	-	-
Loans payable, related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	42	-	-	-	-	-	-	-	-
Promissory notes, related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	210	-	-	-	-	-	-	-	-
Due to related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	369	-	-	-	-	-	-	-	-
Fair value derivative liability - conversion opt at conversion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	708	-	-	-	-	-	-	-	-
CASH, BEGINNING OF YEAR
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33	-	-	-	-
CASH, END OF YEAR
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	-	-	-	-
CASH, END OF PeriodPERIOD
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23